Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
mRNA-1893
- Development stage
- Phase 2
- Lead developer
- Moderna
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
mRNA-1893 is an investigational mRNA-based vaccine developed for the prevention of Zika virus infection. It contains a messenger RNA sequence encoding the structural proteins of the Zika virus, which, when delivered into human cells, directs them to produce viral proteins that assemble into virus-like particles. This mimics natural infection and stimulates an immune response, including production of neutralizing antibodies against Zika virus. Preclinical studies have shown that mRNA-1893 can protect animals from Zika infection and transmission during pregnancy. The vaccine is being developed by Moderna in collaboration with BARDA (Biomedical Advanced Research and Development Authority) and has reached Phase 2 clinical trials for prevention of Zika virus infection in healthy adults[1][2][3][4][5][6].
- Other names
- Zika virus vaccine - Moderna Therapeutics
Beyond the preview
Go deeper on mRNA-1893.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on mRNA-1893.